New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides-Reference-Cited by-同舟云学术

New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tran Truc T.¹²^ORCID,Gomez Villegas Sara¹²,Aitken Samuel L.³^ORCID,Butler-Wu Susan M.⁴^ORCID,Soriano Alex⁵,Werth Brian J.⁶^ORCID,Munita Jose M.⁷⁸^ORCID

Affiliation:

1. Center for Infectious Diseases Research, Houston Methodist Research Institute, Houston, Texas, USA

2. Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA

3. Department of Pharmacy, University of Michigan Health, Ann Arbor, Michigan, USA

4. Department of Pathology, Keck School of Medicine of USC, Los Angeles, California, USA

5. Department of Infectious Diseases, Hospital Clinic of Barcelona, Barcelona, Spain

6. University of Washington School of Pharmacy, Seattle, Washington, USA

7. Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile

8. Genomics & Resistant Microbes (GeRM) Group, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo, Santiago, Chile

Abstract

The long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved by the Food and Drug Administration for acute bacterial skin and soft tissue infections, their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as bloodstream and bone and joint infections.

Funder

HHS | National Institutes of Health

Pfizer

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02614-20

Reference112 articles.

1. CDC. 2019. Antibiotic resistance threats in the United States 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

2. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance

3. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review

4. Oritavancin: A Long-Half-Life Lipoglycopeptide

5. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How I manage severe bacterial infections in people who inject drugs;Clinical Microbiology and Infection;2024-02

2. Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?;Pathogens;2024-01-19

3. Therapeutic drug monitoring of glycopeptide antimicrobials: an overview of liquid chromatography-tandem mass spectrometry methods;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-12

4. Current approach to skin and soft tissue infections. Thinking about continuity of care;Revista Española de Quimioterapia;2023-11-24

5. Complex Outpatient Antimicrobial Therapy: Alternative Management Strategies and Outcomes;Current Infectious Disease Reports;2023-11-04